CY1124893T1 - Φαρμακευτικο μeιγμα μαροπιταντης - Google Patents

Φαρμακευτικο μeιγμα μαροπιταντης

Info

Publication number
CY1124893T1
CY1124893T1 CY20211100549T CY211100549T CY1124893T1 CY 1124893 T1 CY1124893 T1 CY 1124893T1 CY 20211100549 T CY20211100549 T CY 20211100549T CY 211100549 T CY211100549 T CY 211100549T CY 1124893 T1 CY1124893 T1 CY 1124893T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutically acceptable
maropitantis
medicinal mixture
composition
cyclodextrin
Prior art date
Application number
CY20211100549T
Other languages
English (en)
Inventor
Marinus Maria Martinus Boeren
Rudolf Johannes Paridaans
Original Assignee
Le Vet B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57460319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124893(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Le Vet B.V. filed Critical Le Vet B.V.
Publication of CY1124893T1 publication Critical patent/CY1124893T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μια φαρμακευτική σύνθεση που περιλαμβάνει ένα υδατικό διάλυμα κιτρικής μαροπιτάντης, μια φαρμακευτικά αποδεκτή β-κυκλοδεξτρίνη, 7 - 18 mg / ml ενός φαρμακευτικά αποδεκτού συντηρητικού, μια μέθοδο για την παρασκευή της εν λόγω σύνθεσης, που περιλαμβάνει τα στάδια της ανάμιξης, σε ένα υδατικό μέσο, πηγής μαροπιτάντης, πηγής κιτρικής, φαρμακευτικά αποδεκτής β-κυκλοδεξτρίνης και φαρμακευτικά αποδεκτού συντηρητικού. Η εφεύρεση αναφέρεται επίσης στη χρήση της εν λόγω σύνθεσης ως φάρμακο.
CY20211100549T 2015-11-27 2021-06-22 Φαρμακευτικο μeιγμα μαροπιταντης CY1124893T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2015865A NL2015865B1 (en) 2015-11-27 2015-11-27 Maropitant Formulation.

Publications (1)

Publication Number Publication Date
CY1124893T1 true CY1124893T1 (el) 2023-01-05

Family

ID=57460319

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100549T CY1124893T1 (el) 2015-11-27 2021-06-22 Φαρμακευτικο μeιγμα μαροπιταντης

Country Status (12)

Country Link
EP (1) EP3173071B1 (el)
CY (1) CY1124893T1 (el)
DK (1) DK3173071T3 (el)
ES (1) ES2873376T3 (el)
HR (1) HRP20210986T1 (el)
HU (1) HUE054584T2 (el)
LT (1) LT3173071T (el)
NL (1) NL2015865B1 (el)
PL (1) PL3173071T3 (el)
PT (1) PT3173071T (el)
RS (1) RS62057B1 (el)
SI (1) SI3173071T1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL269875B1 (en) 2017-04-10 2024-02-01 Chase Therapeutics Corp NK1 antagonist combination and a method for the treatment of synucleinopathies
KR20200026920A (ko) 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
CN112370451A (zh) * 2020-12-08 2021-02-19 河北科技大学 一种枸橼酸马罗匹坦包合物、注射液及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6340166A (ja) 1986-08-06 1988-02-20 Fuji Xerox Co Ltd 電子写真感光体
MX18467A (es) 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
ES2638113T3 (es) 2004-01-30 2017-10-18 Zoetis Services Llc Conservantes antimicrobianos para lograr una formulación de dosis múltiples usando ciclodextrinas beta para formas de dosificación líquidas
JP4951344B2 (ja) 2004-08-24 2012-06-13 第一三共株式会社 生理活性ペプチド液状製剤
WO2013078500A1 (en) 2011-11-29 2013-06-06 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
CN103637987B (zh) 2013-12-09 2015-12-02 韩彬 羟考酮的液体药物组合物

Also Published As

Publication number Publication date
EP3173071B1 (en) 2021-03-24
RS62057B1 (sr) 2021-07-30
LT3173071T (lt) 2021-07-12
PT3173071T (pt) 2021-04-15
DK3173071T3 (da) 2021-06-28
ES2873376T3 (es) 2021-11-03
PL3173071T3 (pl) 2021-08-16
SI3173071T1 (sl) 2021-11-30
HUE054584T2 (hu) 2021-09-28
HRP20210986T1 (hr) 2021-09-17
NL2015865B1 (en) 2017-06-13
EP3173071A1 (en) 2017-05-31

Similar Documents

Publication Publication Date Title
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1124893T1 (el) Φαρμακευτικο μeιγμα μαροπιταντης
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1124651T1 (el) Αντισωμα εναντι toy her2 και συζευγμα αυτου
UY35907A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmaceuticas que las contienen, así como su uso para la preparación de medicamentos
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
EA201792487A1 (ru) Композиции гидроксипропил-бета-циклодекстринов и способы
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
BR112015018087A8 (pt) composto, composição farmacêutica e uso
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
EA201792591A1 (ru) Фармацевтические препараты
CO7160008A2 (es) Derivados de estra- 1,3,5(10),16- tetraeno 3-sustituidos, métodos para su preparación, prepara-ciones farmaceúticas que los contienen, así como su uso para la preparación de medicamentos
CY1124580T1 (el) Φαρμακευτικα σκευασματα που περιλαμβανουν παραγωγα φαινυλαμινοπυριμιδινης
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
CY1122935T1 (el) Ενισχυτικα της υδατοδιαλυτοτητας που βασιζονται στο γλυκογονο
TR201906476T4 (tr) Farmasötik formülasyonlar.
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
MX2015010486A (es) Composicion masticable para administracion oral y proceso para preparar la misma.